Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rungpetch Sakulbumrungsil has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Khunjira Udomaksorn

    Department of Pharmacy Administration, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkla, 90110, Thailand

    4 shared publications
  • Khunjira Udomaksorn

    Social and Administrative Pharmacy Department, Faculty of Pharmaceutical Sciences, Prince of Songkla University

    3 shared publications
  • Nusaraporn Kessomboon

    Social and Administrative Pharmacy Department, Faculty of Pharmaceutical Sciences, Khon Kaen University

    3 shared publications
  • Nusaraporn Kessomboon

    Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand

    3 shared publications
  • Osot Nerapusee

    Social and Administrative Pharmacy Department, Faculty of Pharmaceutical Sciences, Chulalongkorn University

    3 shared publications
  • Charkkrit Hongthong

    Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand

    2 shared publications

Latest Publications

  • Open Access

    Supporting evidence-informed policy: a multidimensional impact analysis of health technology assessment in Thailand

    by Thanisa Thathong, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Pattara Leelahavarong, Rungpetch C. Sakulbumrungsil

    Introduction: Health Technology Assessment (HTA) is widely used for evidence-informed priority setting in Thailand and has been integrated into pharmaceutical reimbursement decision-making through the National List of Essential Medicines (NLEM). However, its broader contributions have not been systematically assessed. Methods: We retrospectively analyzed 68 completed economic evaluations conducted between 2010 and 2018 using an adapted Payback Framework across five dimensions of impact: informing policy, knowledge production, capacity building, health sector benefit, and an economic dimension assessed separately for approved and rejected items using Net Monetary Benefit (NMB). Results: The principal finding concerns the economic dimension. Among 21 approved technologies, 12 (57.1%) had negative NMB at the national cost-effectiveness threshold, suggesting that adoption would not have been supported on cost-effectiveness grounds alone. Nevertheless, each of these approvals included a structured non-cost-effectiveness justification in committee deliberations, all of which mapped to recognized multi-criteria decision analysis domains, including severity, unmet clinical need, rarity, lack of alternatives, and standard-of-care positioning. This provides empirical evidence that deliberative multi-criteria reasoning operates in routine reimbursement practice in an institutionalized LMIC HTA-to-reimbursement pathway. Among 47 rejected items, 85.1% had positive modeled NMB under a non-adoption sign convention, indicating that non-adoption was consistent with efficient resource use at the threshold. The four categorical dimensions, on a 0-4 ordinal scale, characterized the cohort along complementary axes: informing policy (mean 3.34), health sector benefit (mean 2.54), capacity building (mean 1.97), and knowledge production (mean 1.87). Discussion: These findings suggest that HTA in Thailand contributes to disciplined, transparent multi-criteria priority setting. Aggregate NMB was concentrated in a few large-population, lifetime-horizon studies (14 accounting for 93.6% of the lifetime-horizon total), best interpreted as a descriptive summary rather than a uniform signal. The analytic approach may other insights for other low- and middle-income countries institutionalizing HTA within structured reimbursement systems.

  • Open Access

    Bridging public health emergency and pharmaceutical supply chain preparedness: a scoping review and framework synthesis

    by Kakanang Tosanguan, Nusaraporn Kessomboon, Khunjira Udomaksorn, Osot Nerapusee, Manthana Laichapis, Rungpetch Sakulbumrungsil

    Recent public health emergencies, including the COVID-19 pandemic and large-scale natural disasters, have exposed vulnerabilities in pharmaceutical and hea


  • Open Access

    Pharmacists’ Opinions on the Policy for Controlling the Sale of Drugs That Have Been Abused in Thailand

    by Thanapong Poophalee, Kornkaew Chanthapasa, Rungpetch Sakulbumrungsil, Nusaraporn Kessomboon, Khunjira Udomaksorn

    Background and Objectives: Medication abuse is a major global issue due to its health risks. In Thailand, regulation of drug sales is overseen by the Thai Food and Drug Administration (FDA). This study aimed to examine pharmacists’ opinions on policies regarding the control and monitoring of the sales of drug that have been abused in Thailand. Methods: A mixed-method design was employed, combining a survey of 440 pharmacy pharmacists and 77 regulatory enforcement pharmacists selected through accidental sampling with in-depth interviews of 17 pharmacists recruited via purposive and snowball sampling until data saturation. Survey data were analyzed descriptively, while interview data were examined using content analysis. Data were collected nationwide in Thailand between April and October 2023. Results: Over 80% of respondents understood the policy measures, yet most reported limited effectiveness and unintended consequences. Nearly 90% indicated that maintaining drug sales records drives high-risk buyers to underground markets while increasing workloads and leading some pharmacies to discontinue sales. Respondents favored eliminating or digitalizing records. The FDA Reporter system was viewed as useful, but incomplete and retrospective data limited its effectiveness. Participants recommended real-time integration across the supply chain. Restrictions on retail and wholesale quantities were considered only partially effective, often burdening patients requiring continuous treatment. By contrast, requiring pharmacists to comply with Good Pharmacy Practice (GPP) and personally dispense dangerous drugs was regarded as the most effective measure. Interviews also align with the survey and highlighted persistent issues such as “hanging-license pharmacies” and emphasized stricter enforcement, intersectoral collaboration, and education for at-risk groups. Conclusion: Current measures to control drug sales remain ineffective, leading to diversion, increased workloads, and discontinued sales. Enforcing Good Pharmacy Practice (GPP) has proven more effective. Policy strengthening should focus on modernizing electronic reporting, eliminating rigid quantity limits, and enforcing pharmacist presence during operating hours for safe, responsible drug distribution.


  • Open Access

    Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study

    by Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

    Background: Thailand’s pharmaceutical industry is prioritizing innovation and self-reliance through the development of incrementally modified drugs (IMDs), particularly sustained-release dosage forms. However, the financial feasibility of IMD development remains underexplored. Objective: This study evaluates the financial feasibility of developing sustained-release IMDs in Thailand, focusing on costs, timelines, and investment requirements to inform strategic decision-making. Methods: A mixed methods approach was used, combining literature reviews, expert interviews, and financial modeling. Two scenarios were analyzed: (1) only development (phase I) and (2) full clinical trials (phase I to III). Sensitivity analysis was used to assess the impact of key variables on financial feasibility. Results: The research and development (R&D) process for sustained-release IMDs takes 7 years for phase I–only development, costing US $1.46‐3.09 million, and 11 years for full clinical trials, costing US $18.60‐20.23 million. Process validation batches accounted for 60% of costs in phase I–only scenarios, while clinical trials represented 70% of costs in full clinical trial scenarios. The annual income required for a 5-year payback period ranged from US $0.20‐1.80 million (phase I only) to US $3.01‐27.11 million (full trials). Shorter R&D durations and longer payback periods substantially improved feasibility. Conclusions: Developing sustained-release IMDs in Thailand involves substantial costs and extended timelines but offers a lower-risk alternative to new chemical entities. Strategic investments, efficient R&D processes, and supportive policies are essential to enhance feasibility and alignment with national goals of innovation and self-reliance.


  • Open Access

    Authors’ Response to Peer Reviews of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”

    by Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

    This is the author(s)’ responses to peer review reports related to MS ID#65978

  • Open Access

    Efficiency of Inventory in Thai Hospitals: Comparing Traditional and Vendor-Managed Inventory Systems

    by Sarunya Adirektawon, Anuchai Theeraroungchaisri, Rungpetch C. Sakulbumrungsil

    Background: Traditional procurement and price negotiation methods in public hospitals in Thailand involve group purchasing agreements and bulk orders, posing challenges to improving inventory management efficiency. The vendor-managed inventory (VMI) model is a promising alternative for enhancing hospital performance, especially during crises. This study aimed to assess the potential cost savings in implementing VMI in a large general hospital in Thailand. Methods: A simulation modeling approach was used to compare the current inventory system with three VMI models: VMI1, focused on improving inventory turnover rate (ITR); VMI2, emphasized frequent replenishment with a 1-month supply; and VMI3, eliminated safety stock. Results: The results demonstrated significant cost savings, with potential reductions in total inventory management expenses. Specifically, VMI1 improved ITR from 6.31 to 7.76, reducing average inventory by 36% and cutting management costs by 40%. VMI2, with an ITR of 12.80, reduced inventory by 44% and saved 47% in management costs, while VMI3 achieved a 70% reduction in inventory and a 69% saving in management costs. Conclusions: This study highlights the VMI’s transformative potential in hospital inventory management, demonstrating significant cost savings. However, in the public sector, the feasibility of procurement regulations requires further exploration.


  • Open Access

    Financial Feasibility Study and policy recommendations of Incremental Modified Drugs Development by the Domestic Pharmaceutical Industry

    by Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

    The Thai pharmaceutical industry aims to strengthen its drug system in accordance with the National Strategic Master Plan, emphasizing sustainable development, particularly in biologics and herbal products, to achieve self-reliance. Current efforts are mainly focused on generic drug production, but there’s a significant need for Research and Development (R&D) in Innovative Medicines (IMDs). This study explores the financial feasibility of locally developing an IMDs dosage form. To assess this feasibility, a mixed-methods approach was used, incorporating a literature review, surveys, and interviews. This process involved selecting types of IMDs, constructing financial models, determining cost structures, and conducting a thorough feasibility analysis. The results indicated that a sustained-release dosage form was the most viable option. The analysis took into account total development costs, payback periods, growth rates, and the revenue required to recoup investments. It was found that IMD development is associated with higher costs and longer durations compared to new generic drugs.The study identified several challenges, such as the high cost of clinical studies, extended development times, market feasibility, and drug selection difficulties. Policy recommendations were made to address these challenges, including incentives for clinical studies and fostering industry expertise through collaborative efforts and supportive government policies.In conclusion, the financial feasibility of developing IMDs requires strategic policies and collaboration to overcome these challenges and ensure sustainability. The findings of this study are intended to aid stakeholders in making informed R&D investment decisions.

  • Open Access

    Analysis of pharmaceutical inventory management in a state hospital in Myanmar

    by Mya Pann Thazin, Rungpetch Sakulbumrungsil

    Inventory management analysis for a state-level hospital pharmacy of Myanmar was conducted using ABC-VEN matrix analysis to identify the drug categories that require stringent management control. The annual expenditure of all drug items managed by pharmacy department for the years 2016 and 2017 was analyzed and application of ABC, VEN, and ABC-VEN matrix analysis was performed. The study showed that the average annual expenditure was 288,414 USD. Of the total 297 items of medicines, 7.7% (23), 16.8% (50), and 75.4% (224) were classified as A, B, and C category items, respectively, accounting for 70.4%, 19.7%, and 9.9% of drug expenditure. The VEN analysis revealed that 35.3% (105), 44.8% (133), and 19.9% (59) of items classified as Vital, Essential, and Non-essential category items, respectively, accounting for 65%, 32%, and 3% of drug expenditure. On ABC-VEN matrix analysis, drugs were grouped into Category I (38.0%), Category II (43.1%), and Category III (18.9%) accounting for 82.9%, 15.5%, and 1.5% of drug expenditure. Category I medicines are needed to be controlled strictly whereas Category II and Category III medicines need middle and low level of management, respectively. The ABC-VEN technique was recommended to be used for efficient resource utilization and elimination of wastage and stock-out situations in hospital pharmacies.


  • Open Access

    Factors associated with medication adherence of hypertensive patients in the Philippines: a systematic review

    by Margarita M. Gutierrez, Rungpetch Sakulbumrungsil

    Background: Diseases of the heart and vascular system are the leading cause of mortality in the Philippines. Hypertension, the most important modifiable risk factor, has a prevalence rate of 28% and a control rate of 20%. Despite the proven efficacy of pharmacologic treatment, medication adherence is reported to be as low as 66%. While there are publications that reported factors that affect adherence in Filipinos, there are no existing research that evaluated them systematically. This review is conducted to present and synthesize findings of published literatures.Methods: Databases—PubMed, Scopus, Wiley Online library, Science Direct, JSTOR, Web of Science, SAGE journals, and Cochrane—were used to search for articles published from 2000 to 2020 that studied medication adherence in adult Filipino hypertensive population. Out of the initial 1514 articles, 15 articles met the criteria and were included in the analysis. The evidence from the included studies was summarized and discussed in a narrative review using the World Health Organization framework for adherence to long-term therapies as the framework.Result: The factors that were positively associated with adherence were health care system-related factors: good patient-health provider relationship, accessibility of health services, use of specialty clinics and programs for hypertension, and health insurance. The factors found to be negatively associated with adherence are (1) social economic factors: younger age, single civil status, low educational attainment, and unemployment; (2) patient-related factors: low in health literacy and awareness, knowledge on hypertension, attitude towards hypertension, self-efficacy, and social support; (3) therapy-related factors: inconsistent drug regimen schedule, use of Thiazide and complementary and alternative medicines; (4) condition-related factors: low illness perception, and absence of comorbidities.Conclusions: Findings should be interpreted with caution because of methodological limitations. Despite this, given that health systems related factors are modifiable, they can be the focus of interventions and future researches to increase medication adherence. Clinicians may also want to screen their Filipino hypertensive patients for factors that are associated to low adherence in order to provide a tailored advice. Longitudinal research studies with heterogeneous samples of hypertensive Filipinos are imperative so that targeted interventions can be developed for the population.